930 Brittan Avenue
San Carlos
United States


Show jobs for this employer

About AcureX

Our mission is to halt neurodegenerative diseases starting with Parkinson’s Disease. AcureX expects to have one or more late-preclinical therapeutic candidates for Parkinson’s in human trials within two years, followed by candidates for other neurodegenerative diseases.

AcureX’s approach and founding intellectual property are based on discoveries made by the company’s inventor co-founder, Xinnan Wang MD, Ph.D. Using these insights, AcureX has built a novel mitophagy discovery platform to accelerate drug development and de-risk clinical trials.

The AcureX team is led by veteran scientists with a proven track record in CNS drug development and serial life sciences entrepreneurs.

3 articles with AcureX